Title
Category
Credits
Event date
Cost
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in Acne Vulgaris presented at the 28th Annual Masters of Pediatric Dermatology and the 18th Annual South Beach Symposium:Acne Diagnosis and Treatment in WomenTherapeutic Advancements in Acne & Rosacea TherapyLatest Developments in Lasers and Light Therapies for AcneControversies in Oral Therapy for AcnePediatric Perspective: Video and slide highlights will also be included from the Masters of Pediatric Dermatology conference for learners interested in the pediatric perspective.
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in Atopic Dermatitis (AD) presented at the 28th Masters of Pediatric Dermatology and the 18th Annual South Beach Symposium from high caliber Dermatology physicians below:
  • LivDerm
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Atopic dermatitis is a complex immune disease that has several distinct manifestations across age groups. Published evidence has shown that significant gaps exist in the management of AD, including an under-diagnosis of both children and adults and an incomplete evidence-base for the use of traditional AD therapies across pediatric patients. In addition, most patients and clinicians are not satisfied with current treatments for AD.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Lowering LDL-C effectively and safely is crucial in preventing ASCVD events. Even with the advances in LDL-C-lowering therapy, there is considerable residual risk due to suboptimal adherence, clinical efficacy, or clinical inertia, which increases the chances of serious adverse CV events. Several new and emerging agents may help address these gaps in the near future, and clinicians need to be aware of these new approaches and their potential role in the treatment of high-risk patients with elevated LDL-C.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Familial hypercholesterolemia (FH) remains underdiagnosed and undertreated, which increases ASCVD risk, morbidity and mortality in HF patients.In addition, the relatively low insurance approvals for newer LDL-C lowering agents, even for high-risk FH patients, has limited patients’ access to these necessary therapies, increasing their risk for morbidity and mortality. These challenges in diagnosis and treatment are even more apparent in racial and ethnic minorities.
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Keeping up with pediatric and adult immunization schedules in the COVID-19 era has become significantly more challenging.  Existing problems of vaccine hesitancy and missed opportunities are being exacerbated by physical restrictions, and clinicians are struggling to prioritize services and treatment.  Clinicians need to be aware of pertinent updates to immunization recommendations across the age spectrum in order to keep vaccine-preventable diseases and complications in check.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
During this activity, multidisciplinary experts discuss the evidence with SGLT-2 inhibitors in reducing cardiorenal risk in patients with and without T2DM, as well as offer additional clinical pearls about their application across specialties.This interactive monograph is organized in an easily digestible format, containing a mix of visuals, audio, video, resources, patient cases, as well as news articles and publications, in order to better facilitate the interpretation of the journey of SGLT-2 inhibitors across trials and to patient care.
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Patient with ILDs, especially those with a progressive fibrosis phenotype, maybe at a greater risk for having worse outcomes with COVID-19, including during and post-COVID-19 infection. However, the management of patients with PF-ILDs and COVID-19 is not clear, including the potential management of COVID-19 related lung injury and fibrosis, as well as the overall management of ILDs in the COVID-19 era. During this webcast, experts will discuss these gaps and the implications of COVID-19 in the management of patients with ILDs and PF-ILD.
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The ever-increasing presence of a variety of dermatologic conditions across the lifespan, including in neonates, children, and adolescents continues to be a major challenge for healthcare providers in the United States.  Current estimates predict that up to 30% of primary care visits in the US involve a skin-related issue, with some of the most common conditions including atopic dermatitis, seborrheic dermatitis, contact dermatitis, acne, neonatal rashes, and sunburn among others (Castelo-Soccio 2017).  There is a shortage of pediatric dermatologists in the United States, and more often the

Pages